Legato Capital Management LLC Acquires 12,010 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Legato Capital Management LLC grew its holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 198.8% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 18,050 shares of the specialty pharmaceutical company's stock after acquiring an additional 12,010 shares during the quarter. Legato Capital Management LLC owned 0.08% of ANI Pharmaceuticals worth $1,208,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of ANIP. GAMMA Investing LLC raised its stake in shares of ANI Pharmaceuticals by 163.8% in the first quarter. GAMMA Investing LLC now owns 1,419 shares of the specialty pharmaceutical company's stock valued at $95,000 after purchasing an additional 881 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new position in shares of ANI Pharmaceuticals in the fourth quarter valued at $166,000. Rafferty Asset Management LLC acquired a new position in shares of ANI Pharmaceuticals in the fourth quarter valued at $200,000. Bridgefront Capital LLC acquired a new position in shares of ANI Pharmaceuticals in the fourth quarter valued at $204,000. Finally, Freestone Grove Partners LP acquired a new position in shares of ANI Pharmaceuticals in the fourth quarter valued at $259,000. 76.05% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have issued reports on ANIP shares. Guggenheim reiterated a "buy" rating and set a $86.00 price objective on shares of ANI Pharmaceuticals in a research note on Monday, May 12th. HC Wainwright started coverage on ANI Pharmaceuticals in a research note on Thursday, July 10th. They set a "buy" rating and a $84.00 price objective for the company. Truist Financial increased their price objective on ANI Pharmaceuticals from $62.00 to $65.00 and gave the stock a "hold" rating in a research note on Monday, April 21st. Finally, Wall Street Zen lowered ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Thursday, April 24th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, ANI Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus target price of $78.88.

Insider Transactions at ANI Pharmaceuticals

In related news, insider Christopher Mutz sold 4,000 shares of ANI Pharmaceuticals stock in a transaction that occurred on Wednesday, May 14th. The stock was sold at an average price of $60.45, for a total value of $241,800.00. Following the sale, the insider owned 107,317 shares of the company's stock, valued at approximately $6,487,312.65. This trade represents a 3.59% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Ori Gutwerg sold 881 shares of the business's stock in a transaction that occurred on Thursday, May 15th. The stock was sold at an average price of $60.07, for a total value of $52,921.67. Following the transaction, the senior vice president directly owned 89,897 shares in the company, valued at $5,400,112.79. This trade represents a 0.97% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 5,681 shares of company stock valued at $345,222 over the last 90 days. 11.10% of the stock is owned by company insiders.

ANI Pharmaceuticals Trading Up 1.1%

ANI Pharmaceuticals stock traded up $0.71 during mid-day trading on Friday, hitting $67.48. The stock had a trading volume of 416,041 shares, compared to its average volume of 284,009. The company has a current ratio of 2.66, a quick ratio of 1.98 and a debt-to-equity ratio of 1.46. ANI Pharmaceuticals, Inc. has a 12 month low of $52.50 and a 12 month high of $77.00. The stock has a market capitalization of $1.46 billion, a PE ratio of -53.13 and a beta of 0.57. The stock has a 50-day simple moving average of $63.46 and a two-hundred day simple moving average of $63.05.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last issued its earnings results on Friday, May 9th. The specialty pharmaceutical company reported $1.70 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.37 by $0.33. The firm had revenue of $197.12 million for the quarter, compared to analysts' expectations of $179.75 million. ANI Pharmaceuticals had a positive return on equity of 21.35% and a negative net margin of 3.12%. The company's revenue was up 43.4% compared to the same quarter last year. During the same quarter last year, the business earned $0.82 earnings per share. As a group, sell-side analysts forecast that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current year.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.